← Eichor
Condition: Breast Cancer Brain Metastases Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Breast Cancer Brain Metastases

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06839560Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases
Phase N/A · 2 location(s) · King's College London · NCT06468124Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06718933Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER
NA · 1 location(s) · QIAO LI · NCT07117864Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.
Phase 2 · 1 location(s) · Fudan University · NCT07638852RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastati
Phase 2/Phase 3 · 109 location(s) · Hoffmann-La Roche · NCT07413939Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07100600Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT06418594Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04923542Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to
Phase 3 · 270 location(s) · NRG Oncology · NCT06500455An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastas
Phase 4 · 1 location(s) · City of Hope Medical Center · NCT05376878Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative B
Phase 2 · 3 location(s) · Roswell Park Cancer Institute · NCT04348747Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
Phase N/A · 1 location(s) · Peking University Cancer Hospital & Institute · NCT07251868The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Phase N/A · 18 location(s) · UMC Utrecht · NCT04075305MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer
NA · 1 location(s) · Sunnybrook Health Sciences Centre · NCT06247449A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as
Phase N/A · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06839547Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Phase 1 · 18 location(s) · Duke Street Bio Ltd · NCT06458712Palbociclib and Pembrolizumab In Central Nervous System Metastases
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT02896335Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and A
Phase 2 · 1 location(s) · University of Rochester · NCT04965064Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastase
Phase 2 · 1 location(s) · Medical University of Vienna · NCT05866432Brain Metastasis Development Mechanism in BCBM Patients
NA · 1 location(s) · Samsung Medical Center · NCT06330870A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brai
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06598046Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Me
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06238921Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast Cancer
Phase N/A · 1 location(s) · Center Eugene Marquis · NCT06358625A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Phase 2 · 1 location(s) · Fudan University · NCT04303988Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases
NA · 1 location(s) · The Netherlands Cancer Institute · NCT07511933Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07396454A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.